We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
38 hedge funds and large institutions have $11.8M invested in CASI Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
178% more capital invested
Capital invested by funds: $4.23M → $11.8M (+$7.54M)
36% more funds holding
Funds holding: 28 → 38 (+10)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.16% more ownership
Funds ownership: 0.4% → 0.55% (+0.16%)
Holders
38
Holders Change
+10
Holders Change %
+35.71%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
9
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$509K |
| 3 |
BlackRock
New York
|
+$258K |
| 4 |
PA
Perceptive Advisors
New York
|
+$227K |
| 5 |
Barclays
London,
United Kingdom
|
+$181K |
